Biosimilars: Fact vs Fiction

Understanding biosimilars and their potential for lowering cancer care costs.

Biosimilars_Webinar-Intro-Branded-and-Subtitled-r1

On Wednesday, September 25th, 2019 at 11 am ET join us for Biosimilars: Fact vs Fiction!

About this Webinar

Biosimilars are becoming quite the buzzword in cancer treatment, but cost, regulation, safety and efficacy are driving questions amongst payers and providers. In this webinar, NantHealth and a panel of respected medical experts examine:

  • The true definition of biosimilars and their potential in cancer care
  • The opportunities to drive down costs
  • Common misconceptions and concerns about safety and efficacy
  • Issues around payer reimbursement and provider incentives
  • The role of technology in navigating biosimilars

WEBINAR REGISTRATION


Limited Seats

September 25, 2019
11 AM ET

PANELISTS

Sanjiv S. Agarwala HeadshotSanjiv S. Agarwala, MD
Chief of Medical Oncology at St. Luke’s Cancer Centre
&
Professor of Medicine at Temple University School of Medicine
William Flood HeadshotWilliam Flood, MD
Chief Medical Officer
Eviti, NantHealth
E. Paul Amundson HeadshotE. Paul Amundson, MD, FAAFP
Medical Director, Medical Affairs
CVS Caremark

Over 6,000 oncology practices already use Eviti Connect to submit oncology treatment authorization

Cloropleth_Map_Eviti-V2

Don't forget to register—seats are limited.

Biosimilars: Fact vs Fiction

Understanding biosimilars and their potential for lowering cancer care costs.